Pharma

Your Article Summary

See Latest Articles

FDA approves astellas' vaprisol (conivaptan hydrochloride injection) premixed in 5% dextrose for the treatment of hyponatremia
Astellas, 09/11/09

Astellas Pharma US, Inc. announced that the U.S. Food and Drug Administration has approved a new premixed formulation of Vaprisol: Vaprisol Premixed in 5% Dextrose. Discovered and developed by Astellas, Vaprisol, an arginine vasopressin receptor antagonist, is the first and only approved drug indicated for the treatment of both euvolemic and hypervolemic hyponatremia in hospitalized patients. Hyponatremia is a potentially life–threatening condition that occurs when the body's blood sodium level falls significantly below normal.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Zoster vaccination: A new opportunity for adult immunization
Canadian Journal of Infectious Diseases, 12/15/09

FDA Approves Newly Revised Prescribing Information For Azilect Reducing Medication And Food Restrictions
Teva Pharmaceutical Industries, 12/15/09

Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09

 See all of Drug/Product Approvals